USA Archives

Interview 28 Oct 2022

Migraines: a new vaccine frontier beyond infectious diseases

By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S. company Vaxxinity aims to open a new frontier for vaccines in an effort to reach all patient populations, regardless of location or income. Migraine causes severe headaches that are characterized by throbbing pain and associated symptoms such as sensitivity to […]

October 28, 2022 - 7 minutesmins - By Omnia Ibrahim

elypta renal cell carcinoma kidney cancer

News and Trends 28 Oct 2022

Rila Therapeutics exits stealth mode to address renal fibrosis

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

Persephone Bisociences Microbiome health

Startup Scout 28 Oct 2022

Persephone Biosciences studies the microbiome in baby poop

Disruption in the gut microbiome is linked to a wide range of health problems in newborn babies and patients with cancer. Persephone Biosciences is studying stool samples from these populations to devise bacterial treatments that improve gut health. Research into the gut microbiome has advanced a long way in the last decades. One major boost […]

October 28, 2022 - 6 minutesmins - By Jonathan Smith

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Oct 2022

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […]

October 28, 2022

cancer cell screening drug discovery microplate

News and Trends 26 Oct 2022

Recursion announces $150M private placement

U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

Opinion 25 Oct 2022

Precision medicine research must lose its Eurocentricity

Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […]

October 25, 2022 - 7 minutesmins - By External Contributor

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Migraines: a new vaccine frontier beyond infectious diseases

Rila Therapeutics exits stealth mode to address renal fibrosis

Persephone Biosciences studies the microbiome in baby poop

AKT inhibitor shows signs of effectiveness in patient trial

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

Recursion announces $150M private placement

Precision medicine research must lose its Eurocentricity

Opportunities and challenges for cell and gene therapy investments

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

AbbVie acquires LifeArc portfolio company DJS Antibodies

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!